Letermovir for CMV Prevention in Thoracic Transplant Recipients
This study is testing an oral medication called Letermovir (Prevymis) to prevent cytomegalovirus (CMV) infections in people who have received a heart or lung transplant. CMV is a common virus that can cause problems after transplant surgery. The study aims to see if Letermovir works as well as, or better than, the usual treatment (valganciclovir) and if it causes fewer side effects. You may be able to join if you are 18 or older, have had a heart or lung transplant, and either you or your organ donor tested positive for CMV before the transplant. The study is currently comparing patients receiving Letermovir to those who received standard treatment before the study began.
- Study design
- This is an open-label study, meaning you and your doctors will know you are receiving Letermovir. The study plans to enroll 80 participants.
- What's involved
- You would take Letermovir by mouth for up to 365 days, depending on your specific transplant and CMV status.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your CMV viral load will be checked during the prophylaxis period and up to 180 days after. The proportion of days you received appropriately dosed prophylaxis will be measured between 90 and 365 days after starting the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
At a glance
Conditions
NCT06066957
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Penn Medicine at the University of Pennsylvania
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- CMV viral loadProphylaxis period plus 180 days
The primary outcome will be CMV infection (CMV viremia with CMV viral load \>1,000, CMV syndrome, or tissue invasive CMV disease) during the planned prophylaxis period and the following 180 days
- Proportion of days during which appropriately renally-dosed prophylaxis90 to 365 days post intervention
The primary outcome will be the proportion of days during which appropriately-dosed prophylaxis was received during the planned treatment course.